...
首页> 外文期刊>Western Journal of Emergency Medicine >Troponin Marker for Acute Coronary Occlusion and Patient Outcome Following Cardiac Arrest
【24h】

Troponin Marker for Acute Coronary Occlusion and Patient Outcome Following Cardiac Arrest

机译:肌钙蛋白标记用于心脏骤停后急性冠脉闭塞和患者预后

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Introduction: The utility of troponin as a marker for acute coronary occlusion and patient outcome after out-of-hospital cardiac arrest (OHCA) is unclear. We sought to determine whether initial or peak troponin was associated with percutaneous coronary intervention (PCI), OHCA survival or neurological outcome. Methods: Single-center retrospective-cohort study of OHCA patients treated in a comprehensive clinical pathway from November 2007 to October 2012. Troponin I levels were acquired at presentation, four and eight hours after arrest, and then per physician discretion. Cardiac catheterization was at the cardiologist’s discretion. Survival and outcome were determined at hospital discharge, with cerebral performance category score 1-2 defined as a good neurological outcome. Results: We enrolled 277 patients; 58% had a shockable rhythm, 44% survived, 41% good neurological outcome. Of the 107 (38%) patients who underwent cardiac catheterization, 30 (28%) had PCI. Initial ED troponin (median, ng/mL) was not different in patients requiring PCI vs no PCI (0.32 vs 0.09, p=0.06), although peak troponin was higher (4.19 versus 1.57, p=0.02). Of the 85 patients who underwent cardiac catheterization without STEMI (n=85), there was no difference in those who received PCI vs no PCI in initial troponin (0.22 vs 0.06, p=0.40) or peak troponin (2.58 vs 1.43, p=0.27). Regarding outcomes, there was no difference in initial troponin in survivors versus non-survivors (0.09 vs 0.22, p=0.11), or those with a good versus poor neurological outcome (0.09 vs 0.20, p=0.11). Likewise, there was no difference in peak troponin in survivors versus non-survivors (1.64 vs 1.23, p=0.07), or in those with a good versus poor neurological outcome (1.57 vs 1.26, p=0.14). Conclusion: In our single-center patient cohort, peak troponin, but not initial troponin, was associated with higher likelihood of PCI, while neither initial nor peak troponin were associated with survival or neurological outcome in OHCA patients.
机译:简介:肌钙蛋白在院外心脏骤停(OHCA)后用作急性冠状动脉闭塞和患者预后的标志物的用途尚不清楚。我们试图确定肌钙蛋白的初始或峰值与经皮冠状动脉介入治疗(PCI),OHCA存活率或神经系统预后有关。方法:2007年11月至2012年10月以综合临床途径治疗的OHCA患者的单中心回顾性队列研究。在就诊时,逮捕后4小时和8小时,然后由医生酌情确定肌钙蛋白I水平。心脏导管检查由心脏病专家决定。出院时确定生存率和预后,将脑功能类别评分1-2定义为良好的神经系统预后。结果:我们招募了277例患者; 58%的人有令人震惊的心律,44%的患者存活,41%的神经系统预后良好。在107位(38%)接受了心脏导管插入术的患者中,有30位(28%)接受了PCI。尽管需要肌钙蛋白的峰值更高(4.19 vs 1.57,p = 0.02),但需要PCI的患者与没有PCI的患者的初始ED肌钙蛋白(中位数,ng / mL)没有差异(0.32 vs 0.09,p = 0.06)。在没有STEMI的情况下进行心脏导管插入术的85例患者中(n = 85),初次肌钙蛋白(0.22 vs 0.06,p = 0.40)或峰值肌钙蛋白(2.58 vs 1.43,p = 0.27)。关于结局,幸存者和非幸存者的初始肌钙蛋白无差异(0.09 vs 0.22,p = 0.11),或神经系统结局良好与差的患者(0.09 vs 0.20,p = 0.11)。同样,幸存者和非幸存者的肌钙蛋白峰值无差异(1.64 vs 1.23,p = 0.07),或神经功能良好与较差的患者(1.57 vs 1.26,p = 0.14)。结论:在我们的单中心患者队列中,肌钙蛋白峰值而非初始肌钙蛋白与PCI可能性更高相关,而初始或峰值肌钙蛋白均与OHCA患者的生存或神经学预后无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号